Pre-Clinical Results Show NexACT® Technology Significantly Improves Subcutaneous Delivery & Anti-Metastatic Activity of Angs...
April 28 2010 - 6:47PM
Business Wire
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of
products based on the NexACT® technology, today announced that
results from a pre-clinical study showed significant improvement in
the delivery and half life of Å6, a proprietary peptide treatment
for ovarian cancer currently in Phase 2 development by Angstrom
Pharmaceuticals. Specifically, the incorporation of NexACT® enabled
the dose of Å6 to be cut by half, or from twice per day to once per
day delivered subcutaneously, while achieving the same level of
efficacy in the mouse lung metastasis model.
Bassam Damaj, Ph.D., President and Chief Executive Officer of
NexMed, stated, “These new findings, incorporating the NexACT-A6
peptide formulation, correlate with the half life and delivery
profile of the Å6 compound from Angstrom’s previous studies using
the higher dose. The positive results offer Ångstrom the potential
to clinically test the NexACT-Å6 peptide at much higher doses while
maintaining continuous coverage of the intended therapeutic target
in human patients.” Dr. Damaj further added, “This study was
NexMed’s first entry into the subcutaneous delivery of peptide
drugs, and the results further confirmed the depot-like effect of
the NexACT® technology which we had seen in our subcutaneous
delivery studies with insulin and taxol.”
Malcolm Finlayson, Ph.D., President and Chief Executive Officer
of Ångstrom noted, “Our relationship with NexMed continues to
evolve in a fast and promising way. This new data is very exciting
and warrants further investigation to support the opportunity to
license the NexACT® technology for human clinical trials.”
About Ångstrom Pharmaceuticals
and Å6
Based in San Diego, CA, Ångstrom is developing a new class of
drugs targeting CD44 for the treatment of diseases involving cell
migration, invasion, and metastasis. Results from a completed Phase
1a safety clinical trial on Å6 showed there were no systemic
drug-related adverse events in healthy volunteers. Ångstrom has
also successfully completed a Phase 1b clinical trial evaluating Å6
in women with advanced gynecologic cancer, and a Phase 2 clinical
trial evaluating Å6 in women with asymptomatic CA125 progression of
epithelial ovarian cancer after first-line chemotherapy. Treatments
were well tolerated and more than 40% of the patients dosed
continuously with Å6 experienced disease stabilization. For further
information, go to www.angstrominc.com.
About NexMed
NexMed is the largest specialty CRO based in San Diego, CA and
is one of the industry's most experienced CROs for in vitro and in
vivo pharmacology services and research models. The Company’s goal
is to generate revenues from the growth of its Discovery
Pre-clinical CRO business, while aggressively seeking to monetize
its proprietary NexACT® drug delivery technology through
out-licensing agreements with pharmaceutical and biotechnology
companies, worldwide. At the same time, NexMed is actively pursuing
partnering opportunities for its NexACT®-based treatments for
onychomycosis, psoriasis, sexual dysfunction and cancer. For
further information on NexMed and its subsidiaries, visit the
following websites: http://www.nexmed.com or
http://www.bio-quant.com.
Forward-Looking Statement Safe
Harbor for NexMed
Statements under the Private Securities Litigation Reform Act:
with the exception of the historical information contained in this
release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may
individually or mutually impact the matters herein described for a
variety of reasons that are outside the control of the Company
including but not limited to its ability to out-license the NexACT®
technology, including to Angstrom, or the NexACT®-based products
under development. Additionally, pre-clinical study results
involving animal models of human disease may not be indicative of
the results that could be expected from subsequent clinical trials
in humans.
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Sep 2023 to Sep 2024